 Connection
Christopher Striebich to Antirheumatic Agents
This is a "connection" page, showing publications Christopher Striebich has written about Antirheumatic Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.301 |
|
|
|
-
Conran C, Kolfenbach J, Kuhn K, Striebich C, Moreland L. A Review of Difficult-to-Treat Rheumatoid Arthritis: Definition, Clinical Presentation, and Management. Curr Rheumatol Rep. 2023 12; 25(12):285-294.
Score: 0.192
-
Wampler Muskardin T, Vashisht P, Dorschner JM, Jensen MA, Chrabot BS, Kern M, Curtis JR, Danila MI, Cofield SS, Shadick N, Nigrovic PA, St Clair EW, Bingham CO, Furie R, Robinson W, Genovese M, Striebich CC, O'Dell JR, Thiele GM, Moreland LW, Levesque M, Bridges SL, Gregersen PK, Niewold TB. Increased pretreatment serum IFN-?/a ratio predicts non-response to tumour necrosis factor a inhibition in rheumatoid arthritis. Ann Rheum Dis. 2016 10; 75(10):1757-62.
Score: 0.110
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|